Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PDE4A | P27815 | 2/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419551 | 1.00 | PRMT5 (0.47) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL13107602 | 0.92 | PRMT5 (0.46) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL2149148 | 0.91 | HPGD (0.50) | PRMT5WDR77HPGDPDE4APDE4B | |
| SCHEMBL15600251 | 0.88 | PRMT5 (0.47) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL16415212 | 0.88 | PRMT5 (0.47) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL16520107 | 0.88 | PRMT5 (0.47) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL13677274 | 0.88 | PRMT5 (0.49) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL13677184 | 0.88 | PRMT5 (0.49) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL10281445 | 0.88 | PRMT5 (0.49) | PRMT5WDR77HPGDMEN1ALDH1A1 | |
| SCHEMBL16419552 | 0.88 | NR1H2 (0.50) | PRMT5WDR77HPGDMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2022-03-10 | — | — | US | disclosed |
| US-9585889-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9580416-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-9328118-B2 | Nitrogen-containing bicyclic aromatic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-05-03 | — | — | US | disclosed |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-07 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073511-A1 | INHIBITING (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | PRMT5 2339/4885WDR77 3749/4885HPGD 3060/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | PRMT5 561/4885WDR77 2086/4885HPGD 4517/4885 |
| US-20160228442-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | PRMT5 2147/4885WDR77 3562/4885HPGD 1744/4885 |
| US-20150126488-A1 | NITROGEN-CONTAINING BICYCLIC AROMATIC HETEROCYCLIC COMPOUND | CTSS, CTSV, CTSB | PRMT5 2375/4885WDR77 3556/4885HPGD 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.